Affinity Asset Advisors, LLC
Top Portfolio Positions
97 positions ·
$1,934,339,612 total
· as of Mar 31, 2026
| Ticker | Company | Shares | Value (USD) | % of Portfolio | Open |
|---|---|---|---|---|---|
| SPY |
Spdr S&P 500 ETF Trust
|
200,000 | $130,068,000 | 6.72% | |
| APGE |
Apogee Therapeutics, Inc.
Healthcare
|
1,284,926 | $108,152,221 | 5.59% | |
| XENE |
Xenon Pharmaceuticals Inc.
Healthcare
|
1,675,000 | $97,401,250 | 5.04% | |
| ERAS |
Erasca, Inc.
Healthcare
|
5,350,000 | $86,563,000 | 4.48% | |
| INSM |
INSMED Inc
Healthcare
|
480,000 | $78,489,600 | 4.06% | |
| ROIV |
Roivant Sciences Ltd.
Healthcare
|
2,800,000 | $77,560,000 | 4.01% | |
| SYRE |
Spyre Therapeutics, Inc.
Healthcare
|
1,279,134 | $64,519,518 | 3.34% | |
| OVID |
Ovid Therapeutics Inc.
Healthcare
|
26,271,802 | $58,323,399 | 3.02% | |
| CNTA |
Centessa Pharmaceuticals plc
Healthcare
|
1,400,000 | $55,608,000 | 2.87% | |
| PRAX |
Praxis Precision Medicines, Inc.
Healthcare
|
170,000 | $54,772,300 | 2.83% |
Portfolio Trend
22 quarters · across all stocks
Holdings in NUVL
Shares Held
Position Value (USD)
11 quarters on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $30,735,000 | 300,000 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $32,453,653 | 322,633 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $33,244,382 | 384,417 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $31,664,500 | 415,000 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $32,623,200 | 460,000 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $22,309,800 | 285,000 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $34,526,250 | 337,500 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $15,172,000 | 200,000 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $11,263,500 | 150,000 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $12,878,250 | 175,000 | Shares | Sole | 2024-02-13 | |
| 2023-09-30 | $2,298,500 | 50,000 | Shares | Sole | 2023-11-14 | |
| No 13F history on record for this holder in this stock. | ||||||